Pharmafile Logo
Pharmafocus logo
Advanced Search

CAR-T

Showing 15 posts of 59 posts found.

FDA places hold on Ziopharm CAR-T trial

June 19, 2018
Manufacturing and Production, Research and Development CAR-T, FDA, pharma, ziopharm

CAR-T is emerging as one of the most potentially exciting therapies in the industry, particularly as a beacon for the …

News
fighting_cancer

Looking to the future of oncology

April 9, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR T, CAR-T, Cancer, feature, oncology, pharma

The oncology field moves so quickly that it can be hard to keep track of the latest innovations. Ben Hargreaves …

Feature
handshake2

bluebird backs own CAR-T prospect, takes option to co-develop with Celgene

March 29, 2018
Sales and Marketing Bluebird Bio, CAR T, CAR-T, Celgene, biotech, drugs, pharma, pharmaceutical

Biotech companies showing faith in their own prospect drug candidates is not an unusual occurrence, some do it to extremes. …

News
gilead-sciences

Gilead seals $3bn deal, hoping for off-the-shelf CAR-T

February 23, 2018
Medical Communications, Sales and Marketing CAR-T, Gilead, Kite, Sangamo Therapeutics, biotech, drugs, pharma, pharmaceutical

The expense and laborious process involved in bringing CAR-T therapies to patients was used a key reason for the high …

News
celgene_exteriors-3

Celgene confirms rumours, with $9bn deal for Juno

January 22, 2018
Manufacturing and Production, Sales and Marketing CAR-T, Celgene, biotech, drugs, juno therapeutics, pharma, pharmaceutical

It seems like 2018 may well be the year for M&A that everyone had expected, as two major deals on …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

January 19, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, Boehringer, CAR T, CAR-T, Celgene, Kymriah, Merck KGaA, Novartis, Philippines, Sanofi, gilotrif, juno therapeutics, nestle, top ten

It’s Friday, so it’s time to bring you another run-down of the top ten most popular articles with Pharmafile.com’s readers …

News
novartis_outside_1

Novartis’ CAR T therapy Kymriah scores accelerated approval in both Europe and US

January 17, 2018
Research and Development, Sales and Marketing CAR T, CAR-T, EMA, Europe, FDA, Kymriah, Novartis, US, pharma

Following up last year’s ground-breaking news that CAR T therapy Kymriah had become the first such treatment to be approved …

News
celgene_1_02

Celgene rumoured to be revving up for Juno buyout

January 17, 2018
Research and Development, Sales and Marketing CAR-T, Celgene, Juno, biotech, drugs, pharma, pharmaceutical

Celgene has already started off the year with a bang, announcing a deal with Impact Biomedicines worth a potential $7 …

News
gilead-sciences

Gilead makes $567m strategic acquisition for next-gen CAR-T

December 8, 2017
Medical Communications, Sales and Marketing CAR-T, Cell Design Labs, Gilead, Kite, biotech, drugs, pharma, pharmaceutical

It’s only four months since Gilead completed its buy-out of Kite Pharma for $11.9 billion, but it’s already moving quickly …

News
autolus_-_martin-pule

Promising new CAR-T therapy able to target T-cell lymphoma

November 15, 2017
Research and Development Autolus, CAR T, CAR-T, biotech, drugs, pharma, pharmaceutical

The CAR-T space has progressed rapidly over the last few years, culminating in FDA approvals for Novartis and Gilead to …

News
cellectis

Cellectis given another shot at off-the-shelf CAR-T

November 8, 2017
Medical Communications, Research and Development CAR-T, biotech, cellectis, drugs, pharma, pharmaceutical

It is easy to forget the very real dangers that CAR-T treatment present to patients after Novartis and Gilead both …

News
novartis_hq_day

Novartis aims for CAR-T double-approval in Europe

November 6, 2017
Sales and Marketing CAR-T, Gilead, Juno, Novartis, biotech, drugs, pharma, pharmaceutical

Just last week Novartis revealed it had applied to the FDA for a new indication in diffuse large B-cell lymphoma …

News

Novartis reveals the data behind its showdown with Gilead

November 1, 2017
Research and Development CAR-T, Gilead, Kymriah, Novartis, biotech, drugs, pharma, pharmaceutical

Only yesterday it was revealed that Novartis had applied to the FDA in the same indication that Gilead’s treatment is …

News
_97604447_kymriah-product-shot-8

CAR-T is bringing true precision to the fight against cancer

November 1, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR T, CAR-T, Gilead, Kymriah, Novartis, Yescarta

Matt Fellows investigates how the first-ever CAR-T therapy approvals in the past months could mean the field of cancer treatment …

Feature

Novartis submits second FDA application for CAR-T therapy Kymriah, this time in diffuse large B-cell lymphoma

October 31, 2017
Manufacturing and Production, Sales and Marketing CAR-T, Kymriah, Novartis

Following the “historic” FDA approval of the company’s CAR-T therapy Kymriah (tisagenlecleucel) in the treatment of paediatric and young adults …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023